About me

I’m a Brazilian scientist, born and raised in Rio de Janeiro, currently based in Barcelona, after 10 years living in Germany. My work sits at the intersection of computational biology, multi-omics, and data science, with a focus on translating complex biological signals into insights that can meaningfully accelerate drug development and patient outcomes.

I’m drawn to questions that live at the boundary between basic science and clinical application: how microbial communities shape disease risk, how genomic and epigenomic signals can serve as early biomarkers, and how large-scale biological data can be structured to support regulatory decisions. Over the course of my career I’ve moved deliberately from foundational research toward translational and clinical contexts, and that trajectory continues to define the kind of science I want to do.

I trained in biomedical sciences at the Federal University of Rio de Janeiro State (UNIRIO) before completing a Master’s and doctorate in Computational and Systems Biology at the Oswaldo Cruz Foundation (FIOCRUZ), where I developed my interest in microbial genomics and metagenomics through work on ocean sequencing data from the TARA Oceans project.

From there, I held research and bioinformatics positions across leading European institutions: the Leibniz-Institute for Freshwater Ecology (IGB) and the Berlin Center for Genomics in Biodiversity Research (BeGenDiv) in Berlin; the Max Planck Institute for Biology of Ageing (MPI-AGE) in Cologne; and the German Institute of Human Nutrition (DIfE), where I worked in the Department of Molecular Epidemiology on the EPIC-Potsdam cohort, studying the gut microbiome’s role in cardiometabolic disease across tens of thousands of participants. I also spent time at the Max Delbrück Center (MDC) in Berlin and at Eagle Genomics as Senior Scientist and scientific lead for microbiome projects.

I’m currently Principal Scientist and Head of Computational Biology and Data Science at mBiomics, where I lead the computational function across the full pipeline from discovery to regulatory submission, including the development of analytical frameworks supporting FDA and EMA filings for Live Biotherapeutic Products (LBPs).

Alongside my main roles, I’ve maintained active research interests spanning the global antibiotic resistome (ResistomeDB), cfDNA methylation as a liquid biopsy signal, cardiometabolic multi-omics, and genomic language models for microbial taxonomy. I believe the most interesting science today happens when rigorous computational methods meet real clinical questions, and that is the space I continue to work toward.